HemeRetic

Primary Site Histology Behavior Schema Discriminator 1
C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809 9591 <Any value> 1, 2
C700-C729, C751-C753 9591 3 1, 2
C000-C699, C739-C750, C754-C809 9724, 9727, 9740-9742, 9762-9809, 9811-9820, 9831-9920, 9931-9992 <Any value> <Any value>
C700-C729, C751-C753 9724, 9727, 9740-9742, 9762-9809, 9811-9820, 9831-9920, 9931-9992 3 <Any value>
C000-C699, C739-C750, C754-C809 9751, 9755-9759 <Any value> <Any value>
C000-C440, C442-C689, C691-C694, C698-C699, C739-C750, C754-C809 9930 <Any value> <Any value>
C700-C729, C751-C753 9930 3 <Any value>

Notes

9724, 9727, 9740-9742, 9762-9809, 9811-9820, 9831-9920, 9931-9992 9591 and Schema Discriminator 1: 1, 2 (C000-C440, C442-C689, C691-C694, C698-C809) 9751, 9755-9759 (C000-C699, C739-C750, C754-C809) 9930 (C000-C440, C442-C689, C691-C694, C698-C809) **Note 1:** The following sources were used in the development of this schema * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 83 *Leukemia*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** See the following schemas for the listed histologies * 9591 and Schema Discriminator 1: 3, 9 (C000-C440, C442-C689, C691-C694, C698-C809): *Lymphoma* * 9751, 9755-9759 (C700, C710-C719): *Brain* * 9751, 9755-9759 (C701, C709, C720-C725, C728-C729): *CNS Other* * 9751, 9755-9759 (C751-C753): *Intracranial Gland* * 9930 (C441, C690, C695-C696): *Lymphoma Ocular Adnexa* **Note 3:** Summary Stage is the only applicable staging system for this site/histology/schema. **Note 4:** M-See list of specific histologies below, effective for cases diagnosed 2010 and forward. All primary sites (C000-C809) are included unless otherwise specified. **Note 5:** Schema includes the preferred terms based on the *2017 WHO Classification of Haematopoietic and Lymphoid Tissues* 9591 Splenic B-cell lymphoma/leukemia, unclassifiable (except C441, C690, C695-C696) 9724 Systemic EBV-positive T-cell lymphoma of childhood 9727 Blastic plasmacytoid dendritic cell neoplasm 9740 Mast cell sarcoma 9741 Systemic mastocytosis with an associated hematological neoplasm 9742 Mast cell leukemia 9751 Langerhans cell histiocytosis, disseminated (except C700-C729, C751-C753) 9755 Histiocytic sarcoma (except C700-C729, C751-C753) 9756 Langerhans cell sarcoma (except C700-C729, C751-C753) 9757 Interdigitating dendritic cell sarcoma (except C700-C729, C751-C753) 9758 Follicular dendritic cell sarcoma (except C700-C729, C751-C753) 9759 Fibroblastic reticular cell tumor (except C700-C729, C751-C753) 9762 Heavy chain diseases 9800 Leukemia, NOS 9801 Acute undifferentiated leukemia 9806 Mixed-phenotype acute leukemia with t(9;22)(q34.1;q11.2); *BCR-ABL1* 9807 Mixed-phenotype acute leukemia with t(v;11q23.3); *KMT2A*-rearranged 9808 Mixed -phenotype acute leukemia, B/myeloid, NOS 9809 Mixed-phenotype acute leukemia, T/myeloid, NOS 9811 B-lymphoblastic leukemia/lymphoma, NOS 9812 B-lymphoblastic leukemia/lymphoma with t(9;22))q34.1;q11.2); *BCR-ABL1* 9813 B-lymphoblastic leukemia/lymphoma with t(v;11q23.3); *KMT2A*-rearranged 9814 B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); *ETV6-RUNX1* 9815 B-lymphoblastic/lymphoma with hyperdiploidy 9816 B-lymphoblastic/lymphoma with hypodiploidy (hypodiploid ALL) 9817 B-lymphoblastic/lymphoma with t(5;14)(q31.1;q32.1); IGH/*IL3* 9818 B-lymphoblastic/lymphoma with t(1;19)(q23;p13.3); *TCF3-PBX1* 9820 Lymphoid leukemia, NOS 9831 T-cell large granular lymphocytic leukemia 9832 Prolymphocytic leukemia, NOS 9833 B-cell prolymphocytic leukemia 9834 T-cell prolymphocytic leukemia 9837 T-lymphoblastic leukemia/lymphoma 9840 Pure erythroid leukemia 9860 Myeloid leukemia, NOS 9861 Acute myeloid leukemia, NOS 9863 Chronic myeloid leukemia 9865 Acute myeloid leukemia with t(6;9)(p23;q34.1); *DEK-NUP214* 9866 Acute promyelocytic leukemia with *PML-RARA* 9867 Acute myelomonocytic leukemia 9869 Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26;2); *RBM15-MKL1* 9870 Acute basophilic leukemia 9871 Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); *CBFB-MYH11* 9872 Acute myeloid leukemia, minimal differentiation 9873 Acute myeloid leukemia without maturation 9874 Acute myeloid leukemia with maturation 9875 Chronic myeloid leukemia, *BCR-ABL1*-positive 9876 Atypical chronic myeloid leukemia *BCR-ABL1*-negative 9891 Acute monoblastic and monocytic leukemia 9895 Acute myeloid leukemia with myelodysplasia-related changes 9896 Acute myeloid leukemia with t(8;21)(q22;q22.1), *RUNX1-RUNX1T1* 9897 Acute myeloid leukemia with t(9;11)(p21.3;q23.3); *KMT2A-MLLT3* 9898 Myeloid leukemia associated with Down Syndrome 9910 Acute megakaryoblastic leukemia 9911 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.1); *RBM15-MKL1* 9920 Therapy-related myeloid neoplasms 9930 Myeloid sarcoma (except C441, C690, C695-C696) 9931 Acute panmyelosis with myelofibrosis 9940 Hairy cell leukemia 9945 Chronic myelomonocytic leukemia, NOS 9946 Juvenile myelomonocytic leukemia 9948 Aggressive NK-cell leukemia 9950 Polycythemia vera 9961 Primary myelofibrosis 9962 Essential thrombocythemia 9963 Chronic neutrophilic leukemia 9964 Chronic eosinophilic leukemia, NOS 9965 Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement 9966 Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement 9967 Myeloid/lymphoid neoplasm with *FGFR1* rearrangement 9971 Polymorphic PTLD 9975 Myelodysplastic/myeloproliferative neoplasm, unclassifiable 9980 Myelodysplastic syndrome with single lineage dysplasia 9982 Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia 9983 Myelodysplastic syndrome with excess blasts 9985 Myelodysplastic syndrome with multilineage dysplasia 9986 Myelodysplastic syndrome with isolated del(5q) 9989 Myelodysplastic syndrome, unclassifiable 9991 Refractory neutropenia 9992 Refractory thrombocytopenia

Data Items

Name Default Value Used for Staging NAACCR Item Required By Metadata
Year of Diagnosis <BLANK> No NAACCR #390 None
Primary Site <BLANK> Yes NAACCR #400 None
Histology <BLANK> Yes NAACCR #522 None
Behavior <BLANK> Yes NAACCR #523 None
Schema Discriminator 1 <BLANK> Yes NAACCR #3926 All SSDI
Age at Diagnosis <BLANK> Yes NAACCR #230 None
Tumor Size Clinical 999 No NAACCR #752 None
Tumor Size Pathological 999 No NAACCR #754 None
Tumor Size Summary 999 No NAACCR #756 None
Regional Nodes Positive 99 No NAACCR #820 None
Regional Nodes Examined 99 No NAACCR #830 None
LVI 8 No NAACCR #1182 None
EOD Primary Tumor 999 Yes NAACCR #772 None
EOD Regional Nodes 888 Yes NAACCR #774 None
EOD Mets 88 Yes NAACCR #776 None
SS2018 <BLANK> No NAACCR #764 None
Grade Clinical 8 No NAACCR #3843 CCCR/Canada
COC
NPCR
SEER
SSDI
Grade Pathological 8 No NAACCR #3844 CCCR/Canada
COC
NPCR
SEER
SSDI
Grade Post Therapy <BLANK> No NAACCR #3845 CCCR/Canada
COC
NPCR
SEER
SSDI
JAK2 8 No NAACCR #3862 COC
SEER
SSDI

Initial Context

Staging Methods

Expand All | Collapse All

AJCC Chapter Calculation

Summary Stage 2018

Start

  1. EOD Primary Tumor
  2. ss2018_t

Next Step

  1. EOD Regional Nodes
  2. ss2018_n

Next Step

  1. EOD Mets
  2. ss2018_m

Next Step

  1. Summary Stage - T only
  2. ss2018_derived

End

Outputs

Name Default Value Description NAACCR Item
Schema ID 00830 NAACCR #3800
AJCC ID XX NAACCR #995
Derived Version {{ctx_alg_version}} None
Derived Summary Stage 2018 9 NAACCR #762